GoodRx: Harrow Announces Strategic Partnership with GoodRx

Harrow, Inc. announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx providing patients with discounts on select Harrow products. This initiative reflects Harrow's ongoing commitment to making essential, sight-saving medications accessible and affordable. A core component of Harrow's Access and Affordability Program is reducing the prices of several widely used eyecare products, addressing cost barriers that too often limit patient access. Harrow's program began this week with price reductions for VIGAMOX and MAXIDEX, with the analysis of additional products underway. By lowering these costs, Harrow aims to improve patient access to high-quality eyecare products, ultimately enhancing patient outcomes and overall quality of life. In addition, Harrow has partnered with GoodRx to provide a cash-pay alternative for the purchase of select Harrow products, including FLAREX, ILEVRO, MAXIDEX, TOBRADEX ST, VEVYE, VIGAMOX, and ZERVIATE. This alternative to traditional insurance offers patients discounted pricing through the GoodRx platform. By leveraging GoodRx's reach, Harrow is meeting the needs of those who may not have adequate insurance coverage for the eyecare medications they need.